SUPNSupernus Pharmaceuticals, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though priced for +30% a year vs +9% a year delivered.
Priced for ~30% a year FCF growth. The price demands more than its three-year revenue growth of 9% a year, priced for acceleration.
In its normal range: P/E 27.4 vs a 26.1 median over 34 quarters (+5% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SUPN's price assumes
Today's price asks for 30% free cash flow growth a year; over the last three years Supernus Pharmaceuticals, Inc. delivered −36%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.79%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +30%
Growth the price implies · The price pays for +30% free cash flow growth a year for a decade; the business has delivered −36% a year over the last three.
- Price / book
- 2.29
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.29
- EV / EBIToperating margin −16%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.69
- Free cash flow, trailing twelve months
- $19M
- Market capitalisation58.1 million shares, counted Jul 28, 2026
- $2.36B
- 3-year revenue growth
- +9.4%
- 3-year free cash flow growth
- −36%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #20 of 39 by RyuScore